Published online before print January 18, 2007, doi: 10.1161/01.STR.0000254524.23708.c9
(Stroke. 2007;38:431.)
© 2007 American Heart Association, Inc.
Progress Reviews |
Intracranial Hemorrhage Associated With Revascularization Therapies
From University of Cincinnati (P.K., J.P.B.), Department of Neurology, Cincinnati, Ohio; and the University of Pittsburgh (L.R.W.), Pa.
Correspondence to Pooja Khatri, MD, University of Cincinnati, Department of Neurology, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267-0525. E-mail pooja.khatri{at}uc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionSubtypes of HT and...References |
|---|
Background and Purpose— This review discusses the state of our current knowledge on hemorrhagic transformation (HT) and summarizes key factors to be considered when comparing risk associated with various approaches to revascularization.
Summary of Review— HT is a common and natural consequence of infarction, likely related to matrix metalloproteinases and free radical pathways disrupting permeability barriers between blood and brain during ischemia and reperfusion. Symptomatic HT rates within 24 to 36 hours of stroke are increased in the setting of revascularization therapy regardless of modality. HT incidence rates must be considered in the context of the timing of imaging, the period of the study, the definition of clinically significant HT, and other key predictors of HT. The most consistently identified predictors of clinically significant HT in acute revascularization trials have been thrombolytic therapy, dose of lytic agents, edema or mass effect on head CT, stroke severity, and age. Other risk factors may be hyperglycemia, concurrent heparin use, timing of therapy, and timing of successful recanalization. Future predictors may also include imaging parameters, serological markers, variables related to intra-arterial technique, and arterial lesion location.
Conclusions— Understanding how baseline and treatment variables impact HT rates after acute stroke is critical for those designing and interpreting acute stroke trials. Future trials should consider the use of PH-2 as a standardized safety end point, putting hemorrhagic changes in the context of overall clinical outcome, and developing strategies to reduce the rates of clinically significant intracranial hemorrhage.
Key Words: stroke • ischemia • reperfusion • thrombolysis • endovascular treatment • intracranial hemorrhage
|
Introduction |
|---|
|
TopAbstractIntroductionSubtypes of HT and...References |
|---|
Ever since fibrinolysin was first administered to stroke patients in the 1950s,1 intracranial hemorrhage (ICH) associated with cerebral revascularization therapy has deterred its use. CT imaging in the 1970s ensured that revascularization therapies, such as thrombolytic agents, were rarely administered to patients with hemorrhagic stroke. However, a significant hemorrhage risk associated with revascularization therapy remains.
Clinical trials of thrombolysis for acute ischemic stroke in the 1980s taught us that hemorrhagic transformation (HT) frequently accompanies moderate-to-large ischemic strokes without any specific therapy. We now have a greater understanding of the factors underlying HT in the setting of revascularization therapy, as well as new questions about its clinical significance. This review discusses the state of our current knowledge and summarizes key factors to be considered when comparing risk associated with various approaches to revascularization.
|
Subtypes of HT and their Clinical Significance |
|---|
|
TopAbstractIntroductionSubtypes of HT and...References |
|---|
HT can be categorized based on its association with acute clinical symptoms or its radiological appearance. In either case, the most clinically relevant question is the long-term significance of each subtype. Clearly, if certain HT subtypes are not deleterious, prevention of those subtypes is less important.
Clinically Classified HT
Symptomatic ICH
Symptomatic ICH refers to the presence of HT associated with neurological decline. Recent trials have used a variety of definitions of "decline" (Tables 1 to 5
). ICH is usually attributed to thrombolytics if within 24 to 36 hours of treatment.
|
|
|
|
|
|
Regardless of the definition, data suggest that symptomatic ICH is often devastating, with mortality rates of 45% in National Institute of Neurological Disorders and Stroke (NINDS)2 and 83% in PROACT-II.3 Notably, even subgroups at the highest risk for ICH show a net benefit of treatment with intravenous recombinant tissue plasminogen activator (rt-PA) within 3 hours.4
Asymptomatic ICH
Recent thrombolytic trials have reported significantly higher asymptomatic ICH rates than the NINDS rt-PA trial placebo and treatment groups (Tables 1 to 5
). Variability in detection and definitions of asymptomatic ICH may provide some explanation. CT technique and interpretation have changed over time. For example, during the NINDS rt-PA trial era, head CT scan slice thickness was typically 10 mm, in contrast to the current 5-mm standard.4 Modern CT scanners have increased sensitivity. More frequent use of MR, rather than CT, imaging leads to higher rates of detection of small asymptomatic ICHs.5 MRI has taught us that some subtle hyperdensities on CT do indeed represent hemorrhage. Finally, in the context of intra-arterial (IA) therapy, contrast deposition may be incorrectly classified as ICH. Alternatively, increased asymptomatic ICH rates may partly represent more successful reperfusion strategies. Evidence discussed further below suggests that early and successful reperfusion may lead to higher rates of asymptomatic ICH and accelerate the timing of HT seen in natural history studies.6,7
Determination of the clinical significance of these lesions becomes especially relevant as higher rates of asymptomatic ICH are reported. Post-hoc analyses of both the NINDS and ECASS-II trials, as well as combined analysis of the NINDS and Atlantis A and B trials, showed no impact of asymptomatic ICH on 3-month clinical outcome.8,9,10
Radiographically Classified HT
The ECASS trialists classified HT based on radiological distinctions first proposed by Pessin et al.11,12 They defined 4 categories of HT: (1) hemorrhagic infarction type 1 (HI-1), small petechiae along the margins of the infarct; (2) hemorrhagic infarction type 2 (HI-2), more confluent petechiae within the infarcted area, but without space-occupying effect; (3) parenchymal hematoma type 1 (PH-1), a hematoma in 
30% of infarcted area with some slight space-occupying effect; and (4) parenchymal hematoma type 2 (PH-2), a dense hematoma >30% of the infarcted area with substantial space-occupying effect, or as any hemorrhagic lesion outside the infarcted area.
Compared with placebo groups, only PH-2 rates were higher with rt-PA treatment in both the ECASS-I and ECASS-II trials. In fact, the incidence of HI was lower in the rt-PA groups than placebo in both trials.8,13
In addition, in both ECASS trials, only PH-2s impacted long-term outcome, which was defined as death or severe disability at 3 months after stroke.14,15 Interestingly, PH-1s were associated with only early deterioration, but not long-term clinical outcome. This raises the possibility that not all "symptomatic" hemorrhages adversely impact long-term clinical outcome.
In contrast to PHs, HI-1s may be a marker of good outcome. In ECASS-II, HI-1 was inversely associated with early neurological deterioration (adjusted OR, 0.2; 95% CI, 0.1 to 0.6; P=0.003) and death at 3 months (adjusted OR, 0.2; 95% CI, 0.07 to 0.6; P=0.004).15 In a prospective cohort (n=32) of stroke patients with proximal MCA occlusions treated with rt-PA within 3 hours, those with HI-1 or HI-2 ICHs had smaller infarcts and better clinical outcomes, compared with those without HI (mRS 1.9 versus 3.5; P=0.009) and those with PH-1s and PH-2s (mRS 1.9 versus 4.6; P<0.001).6
Given the varying definitions of "symptomatic" ICH in the stroke literature, comparing PH-2s, or PH-1s and PH-2s combined, between trials may be a more useful strategy, as performed in the pooled analysis of rt-PA trials. Secondary analyses of the ECASS-II trial demonstrated that 73.5% of symptomatic ICHs were PH-1s and PH-2s.8,13 In NINDS, symptomatic ICHs consisted of 70% (14/20) PHs by NINDS definitions (ie, not taking into account mass effect as in the ECASS definitions).16
Incidence of HT: Natural History and Placebo Trial Cohorts
In the absence of revascularization therapy, HT (including all types) is a common and natural consequence of infarction.
Among natural history cohorts, total HT rates range widely, from 6.2% to 43% in small CT-based cohorts.17–21 This wide range is probably best explained by timing of imaging. For example, among natural history cohorts given no anticoagulation or antithrombotics (except low-dose subcutaneous heparin and/or aspirin), the HT rate was 6% within 3 days,19 17% to 26% within 5 to 7 days,18,19 and 43% within 4 weeks.19 Rates of specific ICH subtypes are difficult to determine from natural history cohorts because of limited data and the heterogeneity of definitions.
Among placebo cases from randomized, acute stroke trials, despite the potential for selection or referral bias, ICH rates are generally in keeping with these cohort study rates (Table 1).2,22–26 Key considerations when interpreting ICH rates, in addition to the timing of imaging relative to stroke onset, include definitions of ICH subtypes, the era of the study, and baseline clinical stroke severity among the population in a given trial.
Pathophysiology: HT With and Without Revascularization Therapy
Structurally, evidence suggests that the fundamental mechanism leading to fluid and blood extravasation (ie, vasogenic edema and HT) is disruption of the permeability barriers between the blood and brain, which consist of the endothelial cell tight junctions, referred to as the blood–brain barrier, and the basal lamina consisting of extracellular matrix proteins. This blood extravasation then leads to parenchymal injury through mechanical compression, ischemia, and toxicity of blood components.27 Whether subtypes of HT that are clinically significant represent a continuum of hemorrhages that simply reach a threshold based on size, or whether subtypes are phenomenologically distinct, is debatable.
Our understanding of the biochemical pathways leading to HT is evolving. Some evidence suggests that free radicals produced during ischemia and reperfusion may lead to overlapping molecular changes that activate inflammatory cytokines, which directly and indirectly undermine the integrity of both basal lamina and endothelial tight junctions. More recently, the concurrent activation of proteolytic enzymes that can degrade basal lamina, matrix metalloproteinases (MMPs), have been demonstrated during ischemia and reperfusion.28 In addition, high MMP-9 levels independently predict HT in patients with (OR, 1.31; 95% CI, 1.31 to 70.26; P=0.025) and without thrombolysis (OR, 12; 95% CI, 3 to 51; P<0.001) treatment.29,30 Furthermore, free radical production and MMP induction induce the activity of each other.27,31
In the setting of revascularization, the fundamental question is how much the increased rates of HT are caused by reperfusion and the biochemical pathways discussed, or are specific consequences of the lytic state itself. For example, rt-PA may impact HT rates directly by amplifying MMP-9, increasing NMDA excitotoxicity, and impacting vasoactivity.32,33
Pharmacological strategies to reduce revascularization-induced HT under preclinical investigation include hypothermia, free radical–spin trap compounds, platelet inhibitors, and MMP inhibitors.31,34 Clinical evidence of possible hemorrhage protection by a free radical-trapping agent was suggested by the Phase I SAINT trial of NXY-059. Among rt-PA–treated cases (n=489), those who received NXY-059 (n=240) had significantly less symptomatic ICH than those receiving placebo (N=249; 6.4% versus 2.5%; p-0.036).35 Whether this is a true neuroprotective effect or related to diminished effectiveness of rt-PA remains to be determined.
Risk Factors for Clinically Significant HT
The most consistently identified predictors of symptomatic ICH and/or PH-2s in acute revascularization trials have been thrombolytic therapy, dose of thrombolytic agent, edema or mass effect on head CT, stroke severity, and age (Table 6).
|
Use of Revascularization Therapy
It is well-established that revascularization therapies increase the rate of clinically significant HT. In a pooled analysis of 6 major intravenous rt-PA stroke trials, consisting of 2775 patients, 5.9% of rt-PA and 1.1% of placebo cases had PH-2 hemorrhages (P<0.0001).36
Symptomatic HT rates within 24 to 36 hours of treatment are increased in the setting of revascularization therapy regardless of the modality: intravenous lytics (Table 2), intra-arterial lytics (Table 3), antithrombotics (Table 4), and mechanical devices (Table 5). As with untreated cohorts, these symptomatic ICH rates must be considered in the context of key variables including clinical stroke severity (ie, median baseline National Institutes of Health Stroke Scale [NIHSS]), how "symptomatic" is defined in each trial, the timing of the CT, and the study periods of each specific trial (Tables 2 to 5). Experienced community centers report comparable symptomatic ICH rates after intravenous lytic therapy when the NINDS tPA Stroke Study protocol is strictly followed.24
Symptomatic ICHs tend to occur within the vascular territory of the ischemic insult and they tend to occur relatively early. Only 20% of symptomatic ICHs in the NINDS trial occurred in a clinically silent territory, and no hemorrhages in PROACT-II occurred outside the infarct zone.2,37 In the NINDS trial, all fatal hemorrhages occurred within 24 hours of rt-PA administration, including 80% within 12 hours.4
Rates of symptomatic ICH are generally higher in intra- arterial lytic trials (10% in PROACT-II) compared with intravenous lytic trials (6.4% in NINDS). Likely explanations include the higher baseline median NIHSS scores among intra-arterial subjects (17 in PROACT-II versus 14 in NINDS), longer door-to-needle times, less lacunar subtypes seen in PROACT-II, and differing definitions of "symptomatic."25
Antithrombotic trials using heparins and heparinoids have shown lower HT rates compared with rt-PA. However, their relatively low HT rates remain in excess of their minimal benefit in the acute setting and often included less severely affected subjects.38–40 Newer classes of antithrombotics, such as GP IIb/IIIa inhibitors and direct thrombin inhibitors, are currently under investigation.
In contrast to therapeutic strategies for acute myocardial infarction, symptomatic ICH after revascularization therapy limits the use of aggressive multimodal strategies for reperfusion and prevention of reocclusion in acute ischemic stroke. As discussed below, this was seen in the PROACT trial when high-dose heparin was administered concurrently with intra-arterial thrombolysis.41
Lytic Dose
Several lines of evidence suggest that higher doses of lytics lead to higher hemorrhage rates. In the early pilot trials of rt-PA, 18% (4/22) of patients administered >0.9 mg/kg had symptomatic ICH, compared with 1% (1/72) administered 0.9 mg/kg. (P<0.01)42 In addition, a retrospective analysis of the Multicenter rt-PA Acute Stroke Survey recalculated rt-PA doses using actual weights (rather than weights estimated at the time of rt-PA administration) and showed a trend toward higher rates of ICH at the highest quintile of rt-PA dosing, compared with the lower tiers.43 Finally, the higher rates of symptomatic ICH seen in the streptokinase trials of acute stroke are likely caused in part by the use of the full cardiac dose of streptokinase in these trials.44 By comparison, the rt-PA trials used two-thirds of the cardiac dose of rt-PA, based on dose-escalation pilot trials of rt-PA. Dose-escalation studies of newer generation thrombolytic agents, desmoteplase and tenecteplase, also show increased HT rates with higher lytic doses.22,45 Upcoming phase II studies of desmoteplase and tenecteplase may offer the opportunity to determine whether lower thrombolytic dosing provides the same revascularization efficacy with lower hemorrhage rates.
Clinical Stroke Severity
Clinical stroke severity, as measured by the NIHSS score, was significantly associated with symptomatic ICH in the NINDS trial. (Table 6) It was not associated with PH-2 risk in the ECASS trials, but was associated with HI risk in ECASS-I.8,13
The TOAST trial experience shows how the severity of stroke in a study population can impact an acute stroke trial. In its original inception, the trial tested a 7-day course of the low-molecular-weight heparinoid, danaparoid, among ischemic stroke patients with any significant stroke symptoms. An initial "serious" ICH rate of 12.5% (10/80) was seen in the treated subgroup of enrolled patients with NIHSS scores greater than 15 (versus 1/80 in placebos with NIHSS scores >15; P=0.01). Concerns about this high HT rate led to amending the study protocol to exclude patients with NIHSS scores >15, and the final HT rate was 2.4% among the total 638 patients in the treatment arm.40
Early CT Changes
Another risk factor for symptomatic ICH is the presence of clear CT edema or mass effect. In the NINDS trial, edema was defined as a focal or diffuse area of hypodensity that was less dense (darker) than white matter and denser (whiter) than cerebrospinal fluid. Mass effect was defined as effacement of the cerebral sulci, sylvian fissures, or basal cisterns, or compression of the ventricles. Patients with these CT findings had a 31% (5/16) symptomatic ICH rate, compared with 6% (17/290) without these findings. Edema and/or mass effect on head CT independently predicted symptomatic ICH in multivariate analysis (OR, 7.8; 99% CI, 2.2 to 27.1).4
The ECASS-I trial introduced the concept of excluding patients from revascularization therapy based on CT findings of clear or subtle ischemia in an extended area, such as more than one-third of the MCA territory, based on the concern that these patients would have a higher risk of ICH than benefit from rt-PA. Subsequently, NINDS trial CT scans were retrospectively reevaluated for both clear and subtle early ischemic changes (EICs), defined as the presence of one or more of the following: (1) loss of gray–white matter distinction; (2) hypodensity or hypoattenuation (ie, darker than white matter and whiter than CSF); and (3) compression of CSF spaces. The 31% (194/624) of cases with EICs showed no significantly increased risk of symptomatic ICH after adjusting for baseline NIHSS score. The subset with EICs in more than one-third of MCA territory (N=84) also did not have higher symptomatic ICH rates.46 Another NINDS reanalysis, using the semiquantitive approach of the Alberta Stroke Programme Early CT Scale (ASPECTS), also found that patients with subtle and clear EICs (ASPECTS 7) in more than one-third of MCA territory did not have higher rates of symptomatic ICH.47 Both studies concluded that patients with subtle EICs should not be excluded from rt-PA treatment within 3 hours of symptom onset based on current evidence.
The impact of EICs on CT at the 3- to 6-hour time window may be different. ECASS-II showed a significant association between EICs and both PHs and symptomatic ICH.8 In PROACT II (N=154), nonsignificantly more cases with ASPECTS 7 had symptomatic ICH (OR, 1.9; 95% CI, 0.4 to 9.8)49
Age
Age was the only independent risk factor for PH-2s (P=0.0002), other than thrombolytic administration, in the pooled analysis of major intravenous rt-PA trials.36 Age was also an independent risk factor for both PH and symptomatic ICH in ECASS-II alone.8 Of note, both studies treated predominantly within 3 to 6 hours, and all but one of the pooled trials (ie, NINDS) excluded patients older than 80 years old.
In the only major acute stroke trial without an age exclusion, the NINDS rt-PA trial, posthoc analysis showed that age was not a significant independent predictor of symptomatic ICH.4 In addition, a benefit of rt-PA treatment was shown among older age subgroups.50 Furthermore, the 2 largest cohorts of patients older than 80 years treated with rt-PA demonstrated these findings as well.51,52
Thus, limited data suggest that, although increased age may increase symptomatic ICH risk, rt-PA is likely to benefit older patients.
Other Risk Factors
Hyperglycemia
Baseline glucose >200 was the only risk factor for symptomatic ICH identified in exploratory analysis of the PROACT II trial (36% versus 9% for glucose 200; P=0.022).37 Two large registries have also found hyperglycemia to be a significant risk factor for symptomatic ICH as well.53,54 Glucose may accelerate blood–brain barrier disruption by increasing MMP-9 expression.55
Heparin Dose During IA Therapy
The PROACT trials indicate that the degree of concurrent anticoagulation with thrombolysis also impacts HT rates. In the PROACT-I trial, the first 16 patients received 
10 000 U of heparin (100 IU/kg bolus plus 1000 IU/hx4 hours) and symptomatic ICH rates were 20.0% for placebos and 27.3% for IA thrombolysis patients. In conjunction with these unacceptably high symptomatic ICH rates, partial or complete recanalization rates among the thrombolysis group were 81.8%, which is higher than any other major trial to date.41 The subsequent 24 patients in the trial were administered 4000 U of heparin (2000 IU bolus plus 500 IU/hx4 hours) and symptomatic ICH rates decreased to 0% in placebos and 6.7% in IA lysis cases, whereas recanalization rates decreased to 40.0% in the IA group. Lower dosing regimens of heparin, comparable to the latter regimen, are now used for most intra-arterial procedures.3
Timing of Revascularization Therapy
Longer stroke onset-to-treatment times may be associated with higher rates of symptomatic ICH. Pre-NINDS pilot data with Duteplase showed that those treated at <6 hours had a 25% (15/61) total ICH rate including 8% (5/61) PH-2s. Those treated at 6 to 8 hours had a 53% (17/32) total ICH rate (versus 25%; P=0.012), including 19% (6/32) PH-2s.12,56 The pooled analysis of major rt-PA trials showed nonsignificantly higher rates of parenchymal hematoma at later stroke onset-to-treatment times (P=0.71).36 However, in the DIAS trial, subjects were treated up to 9 hours from stroke onset without an increase in hemorrhage which may be related to MR selection and thrombolytic dose.22
Timing and Success of Recanalization
The timing of actual recanalization may predict symptomatic ICH rates better than the timing of the administration of revascularization therapy.
The hypothesis that recanalization predisposes to HT was first proposed in 1951 by Fisher and Adams, who found persistent arterial occlusions more commonly associated with ischemic infarcts than hemorrhagic infarcts in autopsy cases.57 Subsequent autopsy studies have shown HT in the presence of persistent arterial occlusions. However, these studies cannot exclude the possibility of distal migration of the clot before the HT event or retrograde collateral blood flow leading to reperfusion of an ischemic leaky vascular bed.58
Molina et al showed that PHs may be determined by the timing of recanalization in the setting of rt-PA. By performing serial TCD assessments of recanalization at 6, 12, 24, and 48 hours after stroke, they observed proportionally more total PHs by 36 to 48 hours in late (>6 hours) versus early (<6 hours) recanalizers (50% versus 6%; P=0.025). All PH-2s (n=2) were in the late recanalizing group. In addition, there was a trend toward overall increased HT rate among late recanalizers (35% versus 17%; P=0.12).6
The increased rate of clinically significant ICH seen after revascularization therapies may be related to proportionally later recanalization. Future, large studies confirming this hypothesis are needed. In addition, the timing of recanalization in the context of "physiological time," such as depth and potential reversibility of ischemia, may also be relevant and requires further study.
Additional Considerations
Imaging Parameters
Imaging parameters may also predict HT. Blood–brain barrier permeability is one potential marker based on MRI assessments including hyperintense acute reperfusion marker (HARM), a delayed gadolinium enhancement of the CSF space on fluid-attenuated inversion recovery (FLAIR) MRI imaging,59 early GAD enhancement on T1 images,60 and permeability imaging.61 Persistence and severity of ischemia may also predict HT. This has been suggested by MRI studies assessing diffusion-restriction volume7 and very low or absent apparent cerebral blood volume or flow,62 as well as SPECT studies measuring cerebral blood flow semiquantitatively20 and Xe-CT studies measuring cerebral blood flow quantitatively.63 These parameters all need prospective validation in larger studies with particular attention to their effects on clinically meaningful HT subgroups.
Limited data from cohort studies suggest that previous microbleeds do not significantly increase symptomatic ICH rates after thrombolysis.64 Further study of this issue, including the role of multiple previous microbleeds, is needed.
Serological Predictors
Pretreatment serological predictors of hemorrhage are currently undergoing investigation. A combination of 2 pretreatment endogenous fibrinolysis inhibitors, plasminogen activator inhibitor-1 and thrombin-activated fibrinolysis inhibitor, has been shown to independently predict symptomatic ICH after thrombolysis in a prospective cohort of 77 patients (positive predictive value, 75%; negative predictive value, 97.6%).65 High plasma cellular-fibronectin (c-Fn), a possible marker of vascular endothelial damage, was significantly associated with total ICH after controlling for other relevant risk factors (OR, 2.1; 95% CI, 1.3 to 3.4; P=0.002) in a prospective cohort of 87 patients.66 High MMP-9 levels may be an additional serological marker, as previously discussed. A prospective series of 157 patients showed that PHs after thrombolysis may be related to an "explosive" increase in fibrinogen degradation products, suggesting a possible coagulopathy caused by rt-PA in patients in whom HT develops.67 All of these potential markers need further validation in larger studies.
Antiplatelet Use During Thrombolysis
It is currently standard practice to avoid antiplatelet use during or after thrombolysis. Specifically, the NINDS tPA protocol does not allow for administration of antiplatelet agents during thrombolysis, or up to 24 hours after thrombolysis, because of this concern.2 Limited data suggest that concurrent aspirin use should be avoided. For example, in the MAST-I, patients who received aspirin with streptokinase had higher rates of symptomatic ICH than those who were administered the thrombolytic agent alone (10% versus 6%).68 However, subsequent trials have not found baseline antiplatelet use (within 24 hours before thrombolysis) to be a risk factor for symptomatic ICH (Table 6). Definitive data on this issue is lacking.
IA Technique
Specific predictors of ICH in the intra-arterial revascularization setting have also been suggested. Contrast extravasation seen on a noncontrast CT after intra-arterial thrombolysis, another possible marker of blood–brain barrier permeability and possibly directly toxic, may be an HT risk factor based on several small studies.69 In a retrospective analysis of the Interventional Management of Stroke (IMS) Phase I and II trials of combined intravenous/IA thrombolysis, an increased number of microcatheter contrast injections during the intra-arterial lysis procedure was found to be an independent risk factor of total ICH.70 Postulated mechanisms for this risk include increased contrast extravasation and pressure transmission. These issues also require further study with larger populations, including clinically meaningful HT subgroups.
Lesion Location
Limited data suggest that lesion location may be associated with hemorrhagic complications.71,72 Specifically, internal carotid artery occlusions (versus middle cerebral artery; OR, 4.196; 95% CI, 1.229 to 14.325) and atrial fibrillation (OR, 7.294; 95% CI, 1.567 to 33.956) were the only independent predictors of total hemorrhage in the IMS I trial after controlling for baseline NIHSS score.
Cardioembolic Stroke Subtype
Atrial fibrillation was associated with symptomatic ICH in NINDS and total PHs in ECASS I in univariate analyses only.4,13 In addition, after adjustment for significant covariates, atrial fibrillation was independently associated with symptomatic ICH in a combined analysis of the IMS I and II trials (The IMS I and II Investigators, unpublished results). This analysis may have had increased power to identify atrial fibrillation as a significant risk factor attributable to greater stroke severity and higher rates of atrial fibrillation in the IMS I and II trials compared with the NINDS tPA Stroke Study. The contribution of stroke subtype on ICH risk after revascularization therapy needs further exploration.
Summary: Considerations Regarding HT for Future Acute Stroke Trials
Understanding how baseline and treatment variables impact HT rates after acute stroke is critical for those designing and interpreting acute stroke trials. With this knowledge, key considerations emerge.
First, stroke severity is likely to be a major predictor of symptomatic ICH because it is associated with volume of ischemic brain at risk for hemorrhagic transformation. One needs to consider the median NIHSS score of the study population when interpreting or anticipating symptomatic ICH rates in a given trial or comparing with other trials.
Second, older patients may be at greater risk of symptomatic ICH. Whereas these high-risk patients are likely to benefit from revascularization, their inclusion may prematurely end a trial. Especially in smaller Phase I trials, upper age limits may be needed to allow a promising therapy to be identified. However, this given therapy will need eventual evaluation in older patient subgroups.
Third, higher lytic doses are associated with higher symptomatic ICH risk, but whether lower doses can achieve adequate benefit with less risk is not known. Therefore, new agents must always be evaluated using dose-escalation studies in human stroke patients. Also, because the relationship between increasing efficacy and increasing risk is not well understood, consideration should be given to testing lower doses, not maximizing the dose to a tolerable safety profile.
Fourth, delayed revascularization minimizes benefit and likely increases risk. The goal of acute revascularization should not be just to open occluded vessels, but to open them quickly. Patient selection based on physiological parameters is likely important to reduce late hemorrhage attributable to revascularization as well.
Fifth, future trials should consider using PH-2s as a standardized safety end point. The widely varying definitions of "symptomatic" make clinically relevant comparisons difficult.
Sixth, hemorrhagic changes must always be put in the context of overall clinical outcome. Blood on a scan may not necessarily imply a poor clinical outcome. Whereas symptomatic ICHs and PH-2s can clearly have devastating consequences, asymptomatic ICH and early HI-1 may actually be markers of better clinical outcome.
Finally, in addition to increasing efficacy and good outcomes, future trials of acute stroke therapies should aim to reduce rates of symptomatic ICH or PH-2s.
|
Acknowledgments |
|---|
Disclosures
J.P.B. received a grant from EKOS and provided consultation to Genentech; currently receives drugs from Genentech and devices from Concentric, EKOS, and Johnson & Johnson as principal investigator for ongoing IMS III trial. P.K. participates on IMS III Executive Committee. L.R.W. received grant support from EKOS and is a consultant for ImaRx, Nuvelo, and NTI.
Received August 14, 2006; revision received September 17, 2006; accepted September 20, 2006.
|
References |
|---|
|
TopAbstractIntroductionSubtypes of HT and...References |
|---|
1. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA. 1958; 167: 1705–1709.
2. NINDS rt-PA, Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581–1587.
3. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999; 282: 2003–2011.
4. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997; 28: 2109–2118.
5. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, Butman JA, Patronas N, Alger JR, Latour LL, Luby ML, Baird AE, Leary MC, Tremwel M, Ovbiagele B, Fredieu A, Suzuki S, Villablanca JP, Davis S, Dunn B, Todd JW, Ezzeddine MA, Haymore J, Lynch JK, Davis L, Warach S. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004; 292: 1823–1830.
6. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero F, Codina A. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002; 33: 1551–1556.
7. Tong DC, Adami A, Moseley ME, Marks MP. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. Arch Neurol. 2001; 58: 587–593.
8. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32: 438–441.
9. Libman R, Kwiatkwoski T, Lyden P, Grotta J, Tilley B, Fagen S, Levine S, Broderick J, Lin Y, Lewandowski C, Frankel M, the NINDS rt-PA Stroke Study Group. Asymptomatic Hemorrhagic Transformation of Cerebral Infarction Does Not Worsen Long-term Outcome. J Stroke Cerebrovasc Dis. 2005; 14: 50–54.[CrossRef][Medline] [Order article via Infotrieve]
10. Kent DM, Hinchey J, Price LL, Levine SR, Selker HP. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous. Stroke. 2004; 35: 1141–1146.
11. Pessin MS, Del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol. 1990; 13: 271–289.[Medline] [Order article via Infotrieve]
12. Wolpert S, Bruckmann H, Greenlee R, Wechsler L, Pessin M, del Zoppo G, and the rt-PA. Acute Stroke Study Group. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR. 1993; 14: 3–13.[Abstract]
13. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28: 957–960.
14. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb AP, Lorenzano S, Manelfe C, Bozzao L. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999; 30: 2280–2284.
15. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic. Stroke. 2001; 32: 1330–1335.
16. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006; 37: 556–561.
17. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, Montinaro E, Bozzao L. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996; 46: 341–345.
18. Horowitz SH, Zito JL, Donnarumma R, Patel M, Alvir J. Clinical-radiographic correlations within the first five hours of cerebral infarction. Acta Neurol Scand. 1992; 86: 207–214.[Medline] [Order article via Infotrieve]
19. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction–a prospective study. Stroke. 1986; 17: 179–185.
20. Alexandrov AV, Black SE, Ehrlich LE, Caldwell CB, Norris JW. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke. 1997; 28: 1198–1202.
21. Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S, Fujishima M, Omae T. Hemorrhagic transformation in cerebral embolism. Stroke. 1989; 20: 598–603.
22. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36: 66–73.
23. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000; 31: 811–816.
24. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005; 36: 880–890.
25. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, Investigators ftSE-ASS. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352: 1245–1251.[CrossRef][Medline] [Order article via Infotrieve]
26. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995; 274: 1017–1025.
27. Wang X, Lo EH. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol. 2003; 28: 229–244.[CrossRef][Medline] [Order article via Infotrieve]
28. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001; 21: 1393–1400.[CrossRef][Medline] [Order article via Infotrieve]
29. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003; 34: 40–46.
30. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107: 598–603.
31. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002; 2: 38–43.[Medline] [Order article via Infotrieve]
32. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004; 35: 2726–2730.
33. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006; 66: 1550–1555.
34. Hamann GF, Burggraf D, Martens HK, Liebetrau M, Jager G, Wunderlich N, DeGeorgia M, Krieger DW. Mild to moderate hypothermia prevents microvascular basal lamina antigen loss in experimental focal cerebral ischemia. Stroke. 2004; 35: 764–769.
35. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006; 354: 588–600.
36. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators., ECASS Trials Investigators., NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363: 768–774.[CrossRef][Medline] [Order article via Infotrieve]
37. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001; 57: 1603–1610.
38. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997; 349: 1569–1581.[CrossRef][Medline] [Order article via Infotrieve]
39. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O’Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001; 358: 702–710.[CrossRef][Medline] [Order article via Infotrieve]
40. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998; 279: 1265–1272.
41. del Zoppo G, Higashida R, Furlan A, Pessin M, Rowley H, Gent M, Investigators atP. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998; 29: 4–11.
42. Levy D, Brott T, Haley E Jr, Marler J, Sheppard G, Barsan W, Broderick J. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994; 25: 291–297.[Abstract]
43. Messe SR, Tanne D, Demchuk AM, Cucchiara BL, Levine SR, Kasner SE Dosing errors may impact the risk of rt-PA for stroke: the multicenter rt-PA acute stroke survey, J Stroke Cerebrovasc Dis. 2004/0; 13: 35–40.[CrossRef]
44. Cornu C, Boutitie F, Candelise L, Boissel JP, Donnan GA, Hommel M, Jaillard A, Lees KR. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. Stroke. 2000; 31: 1555–1560.
45. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke. Stroke. 2005.
46. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM, National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001; 286: 2830–2838.
47. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR, NINDS rtPA Stroke Study Group NIH. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke. 2005; 36: 2110–2115.
48. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006; 37: 973–978.
49. Hill MD, Rowley HA, Adler F, Eliasziw M, Furlan A, Higashida RT, Wechsler LR, Roberts HC, Dillon WP, Fischbein NJ, Firszt CM, Schulz GA, Buchan AM, PROACT-II Investigators. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke. 2003; 34: 1925–1931.
50. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997; 28: 2119–2125.
51. Sylaja PN, Cote R, Buchan AM, Hill MD Thrombolysis for acute ischemic stroke patients aged 80 years and older: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006.
52. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (
80 years) stroke patients. Stroke. 2005; 36: 2421–2425.
53. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105: 1679–1685.
54. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30: 34–39.[Medline] [Order article via Infotrieve]
55. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 2006; 37: 267–273.
56. del Zoppo G, Poeck K, Pessin M, Wolpert S, Furlan A, Ferbert A, Alberts M, Zivin J, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr J, Feldman E, Hacke W, Kase C, Biller J, Gress D, Otis S. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32: 78–85.[CrossRef][Medline] [Order article via Infotrieve]
57. Fisher M, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol. 1951; 10: 92–94.[Medline] [Order article via Infotrieve]
58. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993; 5: 1–16.[Medline] [Order article via Infotrieve]
59. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke. 2004; 35: 2659–2661.
60. Kim EY, Na DG, Kim SS, Lee KH, Ryoo JW, Kim HK. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR Am J Neuroradiol. 2005; 26: 1050–1055.
61. Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005; 26: 2213–2217.
62. Alsop DC, Makovetskaya E, Kumar S, Selim M, Schlaug G. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke. 2005; 36: 746–750.
63. Gupta R, Yonas H, Gebel J, Goldstein S, Horowitz M, Grahovac SZ, Wechsler LR, Hammer MD, Uchino K, Jovin TG Reduced Pre-treatment Ipsilateral MCA Cerebral Blood Flow is Predictive of Symptomatic Hemorrhage Post Intra-arterial thrombolysis in Patients with MCA occlusion. Stroke. 2006; In Press.
64. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006; 66: 165–171.
65. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004; 35: 2123–2127.
66. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004; 35: 1671–1676.
67. Trouillas P, Derex L, Philippeau F, Nighoghossian N, Honnorat J, Hanss M, Ffrench P, Adeleine P, Dechavanne M. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke. 2004; 35: 1323–1328.
68. Multicentre Acute Stroke Trial-Italy (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995; 346: 1509–1514.[CrossRef][Medline] [Order article via Infotrieve]
69. Yoon W, Seo JJ, Kim JK, Cho KH, Park JG, Kang HK. Contrast enhancement and contrast extravasation on computed tomography after intra-arterial thrombolysis in patients with acute ischemic stroke. Stroke. 2004; 35: 876–881.
70. Khatri P, Broderick JP, Khoury JC, Carrozzella J, Tomsick T. Microcatheter Contrast Injections During Intra-arterial Thrombolysis Increase Intracranial Hemorrhage Risk. Stroke. 2006; 37: 622.
71. Suarez JI, Sunshine JL, Tarr R, Zaidat O, Selman WR, Kernich C, Landis DM. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 1999; 30: 2094–2100.
72. IMS Study Investigators. Hemorrhage in the Interventional Management of Stroke study. Stroke. 2006; 37: 847–851.
73. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill MD, Wojner AW, CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004; 351: 2170–2178.
74. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282: 2019–2026.
75. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial–Europe Study Group. N Engl J Med. 1996; 335: 145–150.
76. Levy D, Principal Investigator. Stroke Treatment with Ancrod Trial (STAT). Stroke. 1997; 28: 2106.
77. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, Brown PM, ARGIS-1 Investigators. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004; 35: 1677–1682.
78. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000; 355: 1205–1210.[CrossRef][Medline] [Order article via Infotrieve]
79. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004; 35: 904–911.
80. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999; 30: 2598–2605.
81. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol. 2006; 27: 1177–1182.
82. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP, MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005; 36: 1432–1438.
83. Gobin YP, Starkman S, Duckwiler GR, Grobelny T, Kidwell CS, Jahan R, Pile-Spellman J, Segal A, Vinuela F, Saver JL. MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke. 2004; 35: 2848–2854.
84. Mahon BR, Nesbit GM, Barnwell SL, Clark W, Marotta TR, Weill A, Teal PA, Qureshi AI. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. AJNR Am J Neuroradiol. 2003; 24: 534–538.
This article has been cited by other articles:
 |
|
 |
|
  C. Dai, S. Wang, X. Zhang, G. Ma, S. Lin, and L. Wang Stent Placement in Acute Cerebral Artery Occlusion Stroke, July 1, 2009; 40(7): e503 - e503. [Full Text] [PDF]
|
|
|
|
 |
|
 T Kharitonova, M Thoren, N Ahmed, J M Wardlaw, R von Kummer, L Thomassen, N Wahlgren, and for the SITS investigators Disappearing hyperdense middle cerebral artery sign in ischaemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick Endovascular Therapy for Acute Ischemic Stroke Stroke, March 1, 2009; 40(3_suppl_1): S103 - S106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Nogueira, W. S. Smith, and on Behalf of the MERCI and Multi MERCI Writing Com Safety and Efficacy of Endovascular Thrombectomy in Patients With Abnormal Hemostasis: Pooled Analysis of the MERCI and Multi MERCI Trials Stroke, February 1, 2009; 40(2): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.A. Christoforidis, C. Karakasis, Y. Mohammad, L.P. Caragine, M. Yang, and A.P. Slivka Predictors of Hemorrhage Following Intra-Arterial Thrombolysis for Acute Ischemic Stroke: The Role of Pial Collateral Formation AJNR Am. J. Neuroradiol., January 1, 2009; 30(1): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pancioli, J. Broderick, T. Brott, T. Tomsick, J. Khoury, J. Bean, G. del Zoppo, D. Kleindorfer, D. Woo, P. Khatri, et al. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial Stroke, December 1, 2008; 39(12): 3268 - 3276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bose, H. Henkes, K. Alfke, W. Reith, T.E. Mayer, A. Berlis, V. Branca, S. P. Sit, and for the Penumbra Phase 1 Stroke Trial Investigator The Penumbra System: A Mechanical Device for the Treatment of Acute Stroke due to Thromboembolism AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1409 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khatri, S. E. Kasner, and D. Kolansky Reply J. Am. Coll. Cardiol., July 22, 2008; 52(4): 317 - 318. [Full Text] [PDF]
|
|
|
|
|
|
P. Khatri, R. A. Taylor, V. Palumbo, V. Rajajee, J. M. Katz, J. A. Chalela, A. Geers, J. Haymore, D. M. Kolansky, S. E. Kasner, et al. The safety and efficacy of thrombolysis for strokes after cardiac catheterization. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. van der Worp and J. van Gijn Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 572 - 579. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm Stroke, August 1, 2007; 38(8): 2279 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Demaerschalk Thrombolytic Therapy for Acute Ischemic Stroke: The Likelihood of Being Helped Versus Harmed Stroke, August 1, 2007; 38(8): 2215 - 2216. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||